Kenvue Inc. (NYSE:KVUE) Shares Bought by Cromwell Holdings LLC

Cromwell Holdings LLC lifted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 190.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,341 shares of the company’s stock after acquiring an additional 4,159 shares during the quarter. Cromwell Holdings LLC’s holdings in Kenvue were worth $147,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Manchester Capital Management LLC raised its position in Kenvue by 80.8% in the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after purchasing an additional 530 shares in the last quarter. Riverview Trust Co acquired a new stake in Kenvue in the third quarter valued at approximately $30,000. MV Capital Management Inc. lifted its stake in Kenvue by 71.2% in the first quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock worth $33,000 after acquiring an additional 642 shares during the last quarter. Salomon & Ludwin LLC acquired a new position in Kenvue during the 1st quarter worth approximately $33,000. Finally, Studio Investment Management LLC increased its position in shares of Kenvue by 52.1% in the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock valued at $45,000 after purchasing an additional 845 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Performance

NYSE KVUE opened at $22.64 on Friday. The firm has a market cap of $43.36 billion, a P/E ratio of 39.03, a P/E/G ratio of 3.00 and a beta of 1.40. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $23.55. The business’s 50-day moving average price is $22.41 and its 200 day moving average price is $20.29. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE) last released its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.04. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The business had revenue of $4 billion for the quarter, compared to analyst estimates of $3.93 billion. During the same quarter in the previous year, the company posted $0.32 earnings per share. The company’s revenue for the quarter was down .3% compared to the same quarter last year. On average, equities research analysts expect that Kenvue Inc. will post 1.08 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be issued a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.62%. The ex-dividend date is Wednesday, November 13th. Kenvue’s payout ratio is 141.38%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on KVUE shares. Bank of America boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday. Jefferies Financial Group began coverage on Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price on the stock. Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a report on Tuesday, September 24th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. upped their target price on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and a consensus price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.